Review

Bioactive Candy: Effects of Licorice on the Cardiovascular System

Mikkel R. Deutch ¹, Daniela Grimm ¹,²,³, Markus Wehland ², Manfred Infanger ² and Marcus Krüger ²,*

¹ Department of Biomedicine, Aarhus University, 8000 Aarhus C, Denmark; mikkelrd@gmail.com (M.R.D.); dgg@biomed.au.dk (D.G.)
² Clinic for Plastic, Aesthetic and Hand Surgery, Otto von Guericke University, 39120 Magdeburg, Germany; markus.wehland@med.ovgu.de (M.W.); manfred.infanger@med.ovgu.de (M.I.)
³ Gravitational Biology and Translational Regenerative Medicine, Faculty of Medicine and Mechanical Engineering, Otto von Guericke University, 39120 Magdeburg, Germany
* Correspondence: marcus.krueger@med.ovgu.de; Tel.: +49-391-67-21267

Received: 24 September 2019; Accepted: 9 October 2019; Published: 14 October 2019

Abstract: Licorice, today chiefly utilized as a flavoring additive in tea, tobacco and candy, is one of the oldest used herbs for medicinal purposes and consists of up to 300 active compounds. The main active constituent of licorice is the prodrug glycyrrhizin, which is successively converted to 3β-monoglucuronyl-18β-glycyrrhetinic acid (3MGA) and 18β-glycyrrhetinic acid (GA) in the intestines. Despite many reported health benefits, 3MGA and GA inhibit the 11-β-hydrogenase type II enzyme (11β-HSD2) oxidizing cortisol to cortisone. Through activation of mineralocorticoid receptors, high cortisol levels induce a mild form of apparent mineralocorticoid excess in the kidney and increase systemic vascular resistance. Continuous inhibition of 11β-HSD2 related to excess licorice consumption will create a state of hypernatremia, hypokalemia and increased fluid volume, which can cause serious life-threatening complications especially in patients already suffering from cardiovascular diseases. Two recent meta-analyses of 18 and 26 studies investigating the correlation between licorice intake and blood pressure revealed statistically significant increases both in systolic (5.45 mmHg) and in diastolic blood pressure (3.19/1.74 mmHg). This review summarizes and evaluates current literature about the acute and chronic effects of licorice ingestion on the cardiovascular system with special focus on blood pressure. Starting from the molecular actions of licorice (metabolites) inside the cells, it describes how licorice intake is affecting the human body and shows the boundaries between the health benefits of licorice and possible harmful effects.

Keywords: licorice; glycyrrhizin; glycyrrhetinic acid; glabridin; 11-β-dehydrogenase isozyme 2; hyperaldosteronism; hypokalemia; hypertension

1. The Sweet “Father of Herbal Medicine”

Licorice is the root of the legume Glycyrrhiza glabra (Figure 1a) that grows in varieties in warm areas like the Middle East, Asia and Southern Europe. It is one of the oldest used herbs in ancient medicine and referred to as “the father of herbal medicine” [1]. Licorice, from which a sweet flavor can be extracted, has been used in herbal and traditional medicine in both Eastern and Western cultures dating back to beyond 4000 BC [2]. The early Egyptians and Assyrians are known to have cultivated the ‘sweet root’ that was later imported to China, where it has been used for centuries under the name ‘Gan Cao’ [3]. It has also been described by ancient Greeks, including Hippocrates and Theophrastus, as well as by Romans [2,4]. Today, the Scandinavian countries seem to have the most consumers of licorice; however, licorice intake is also a popular strategy to quench thirst...
during Ramadan (based on its historical utilization in the desert or on battlefields, where travelers and soldiers drank licorice extracts to combat thirst sensation on long marches). Although the main active compound glycyrrhizin is considered to be 50-times sweeter than sucrose [5], licorice is rarely used for sweetening purposes alone due to its associated flavor and the brownish color that would be imparted to non-acidic foods [2,6]. Since the 18th century, the primary use comprises mainly licorice extracts (in pharmacy called *Succus liquiritae*) as a flavoring additive in tea, tobacco, candy (Figure 1b) and other sweets, but the licorice root itself (*Liquiritae radix*) is still used as a dietary supplement in some parts of the world [7]. Among people preferring alternative or complementary medicine, historical uses for licorice were revived and are still practiced today [8–10].

![Image](a) ![Image](b)

**Figure 1.** (a) Inflorescence of *Glycyrrhiza glabra* L.; (b) licorice-containing candies; (c) chemical structure of the prodrug glycyrrhizin (C₁₂H₂₅O₁₆), the main active compound of licorice. The molecule consists of two molecules of glucuronic acid (left) that are linked to 18β-glycyrrhetinic acid; (d) chemical structure of glabridin (C₂₀H₂₀O₄), a further bioactive licorice compound. Colors indicate molecule structures used in following schematics.

On the one hand, the health benefits ascribed to licorice are numerous: for centuries it has been used in herbal and folk medicine to treat multiple diseases such as gastrointestinal symptoms and respiratory diseases [10]. The broad spectrum of activities known today comprises immunostimulatory and anti-ulcer effects [11–13], anti-viral and anti-microbial effects [14,15], hepatoprotective [16,17], anti-carcinogenic [18] and several other positive effects that contribute to the protection of the nervous, respiratory, endocrine and cardiovascular system [9]. Licorice is also effective against gastrointestinal problems by repairing the inner layer of the stomach and cleansing the respiratory system by increasing the production of mucus. Furthermore, other extracts of the licorice root have been tested in the treatment of gastritis induced by *Helicobacter pylori* and showed promising results [19,20]. The polyphenolic flavonoid glabridin possesses hypoglycemic effects by modulating glucose and
lipid metabolism [21,22], similar to effects attributed to green tea extract [23]. On the other hand, it is well-known that consuming excessive quantities of licorice can impact upon cardiometabolic health by elevating blood pressure (BP), and thus, may be a cause of hypertension and other cardiovascular complications [24–30].

Hypertension is one of the major concerns for our healthcare system and was the leading contributor to premature death in 2015 [31]. Due to the higher arterial BP, it has been proven to be a major risk factor of cardiovascular diseases (CVD). The global prevalence of hypertension was estimated to be about 1.13 billion. Generally, hypertension is the cut-off BP value, where the benefits of treatment outweigh the associated risks. According to the European Society of Cardiology (ESC) “hypertension” is defined as a systolic BP ≥ 140 mmHg and a diastolic BP ≥ 90 mmHg [32]. Hypertension is divided into primary and secondary forms. It is a multifactorial disease, where the contribution of different factors is variable and with a small effect size. Most of the patients have no clear etiology, and they are classified as having primary hypertension. According to Charles et al. [33], about 5–10% of hypertensive patients have secondary hypertension, a result of a different disease affecting the cardiovascular system, such as renal diseases, primary hyperaldosteronism or obstructive sleep apnea.

Licorice and other drugs affecting the hormonal regulation of the water and electrolyte balance could be causing primary hypertension. To examine the actual cause of hypertension, some tests are needed. This would include measurements of plasma aldosterone and plasma renin. Aside from licorice, plenty of additional risk factors increase the possibility of developing hypertension [32].

In this review, we summarized and evaluated current literature about the effects of licorice ingestion on the cardiovascular system with special focus on BP. The literature was primarily identified using online databases. The search was completed on 24/9/2019. The primary registers included PubMed, Embase and ClinicalTrials.gov. Keywords that were used in the search included both “licorice” and “liquorice”. Both variations were used to ensure a more complete search, since “licorice” is widely used in American literature whereas “liquorice” is common in British literature. In PubMed, the search for “liquorice” alone gave 4347 results, while “liquorice and hypertension” narrowed it down to 364 results. “Liquorice and cardiovascular disease” gave 379 results; “Glycyrrhiza and hypertension” resulted in 255 hits. We thoroughly collected information about the molecular and physiological mechanisms of licorice in order to explore the effects and prevalence of licorice intake in general. This way, we want to show the boundaries between its health benefits and possible harmful effects.

2. Pharmacological Effects of Licorice

2.1. Licorice Digestion and Chemistry of Metabolites

Licorice consists of up to 300 active compounds comprising phenolic acids, flavonoids, flavans, chalcones, isoflavans (including glabridin, the main compound found in the hydrophobic fraction of licorice extract) and isoflavonoids [10]. A species-dependent content of 3 to 5% the triterpenoid saponin glycyrrhizin (Figure 1c) accounts for the sweet taste of licorice root and is the main active constituent of licorice [6,34]. Although the presence of glycyrrhizin in licorice has been known for over 200 years, detailed chemical investigations have not been conducted until the mid of the 20th century [35]. In the licorice root, tribasic glycyrrhizin naturally occurs in form of its calcium and potassium salts. After oral ingestion, glycyrrhizin (which itself possesses only poor oral bioavailability) is successively hydrolyzed to 3β-monoglucuronyl-18β-glycyrrhetinic acid (3MGA) and the aglycone 18β-glycyrrhetinic acid (GA; also known as enoxolone) by intestinal bacteria possessing specialized β-glucuronidases [36,37]. GA is often considered as the active metabolite of licorice [38–40], but its pharmacokinetics seem to be more complex. After rapid absorption from the gut, 3MGA and GA circulate in the bloodstream. From there, they are transported to the liver by carrier molecules, where they are metabolized (Figure 2). In humans, hepatic processing is not yet clearly defined, but it is apparent that each metabolite can undergo further conjugation or reduction followed by biliary
The products are likely re-metabolized by the gut microbiome and thereby subjected to enterohepatic recycling requiring several days for complete elimination [41].

Figure 2. Suggested glycyrrhizin metabolism. Dependent on the gut microbiome glycyrrhizin is stepwise hydrolyzed to 3β-monoglucuronyl-18β-glycyrrhetinic acid (3MGA) and 18β-glycyrrhetinic acid (GA; blue structure) in the intestines. Both 3MGA and GA were absorbed from the gut and transported systemically in the bloodstream. In the liver, they undergo hepatic biotransformation before products were excreted via bile. The flavonoid glabridin (yellow structure) is also absorbed from the gut and circulates in the blood in its aglycone form. The hepatic metabolization of glabridin is not shown here. Green hexagons: glucuronic acid. Parts of the figure were drawn by using pictures from Servier Medical Art (http://smart.servier.com), licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0).
The further bioactive constituent, glabridin (Figure 1d), has shown low oral bioavailability in rats. Microsomal studies by Cao et al. [42] demonstrated that glabridin is mainly metabolized by hepatic glucuronidation. They also found that the intestine contributes to glabridin glucuronidation to a much lesser extent. After the intestinal absorption process involving P-glycoprotein, glabridin appears in the human plasma and in the liver as the free (aglycone) form that also circulates within the bloodstream [43,44].

The digestion of licorice is still not completely understood. Interestingly, the bioavailability of glycyrrhizin is reduced when consumed as licorice [45], suggesting that some components of the licorice root may interact with glycyrrhizin during intestinal absorption, reducing its oral bioavailability [46]. Some recent animal studies on rats indicated that there might be further metabolites of GA as causal candidates for the described pharmacological effects [47,48]. In addition, it should be mentioned that the enterohepatic circulation of GA has not yet been studied in humans. However, similar steps can be expected, because GA metabolites can be hydrolyzed by human gastrointestinal bacteria as well [6].

2.2. Pharmacodynamics of Licorice Constituents and Metabolites

Licorice intake induces physiological effects similar to aldosterone and corticosteroids. Resembling steroid-like structures, both 3MGA and GA are able to bind to the mineralocorticoid receptor (MR) in the distal tubules of the kidney (direct effect), although competitive binding assays revealed that the affinities of MR for licorice metabolites were up to 10,000 times weaker than those for adrenocortical hormones [49]. In a normal physiological state, MR is activated by aldosterone to increase sodium and water resorption into the blood and potassium excretion into the urine mediating sodium and water homeostasis within the kidneys. However, it is unclear how the direct effects of 3MGA and GA on MR contribute to the effect of licorice. Although there is some evidence of this direct effect in vitro [50], the relative affinity for MR compared to aldosterone as well as low serum levels of GA after licorice consumption, which did not reach the concentrations necessary to affect aldosterone or cortisol binding to MRs in humans, question that theory [51]. In addition, hyper-mineralocorticosteroid effects were not observed in patients or animals with severe adrenal insufficiency [52]. It is much more likely that metabolites of glycyrrhizin promote a change in cortisol metabolism [53]. Cortisol acts as an agonist for aldosterone to activate MR with equal affinity but circulates in 100–1000-times higher plasma concentrations than that of aldosterone. In adult tissues, the type II isozyme of 11β-hydroxysteroid dehydrogenase (11β-HSD2) is expressed in the distal nephron of the kidney [54], in smooth muscle cells and endothelial cells of the vascular wall [55], in the heart [56] and in the brain [57], where it serves to protect the MR from being overly activated by cortisol [53,58]. 11β-HSD2 converts ‘active’ cortisol to the ‘inactive’ cortisone which has a very low affinity for MR. Monder et al. [59] described a strong inhibitory effect of GA for 11β-HSD2 using rat kidney homogenates for in vitro analysis. In addition, oral glycyrrhizin administration inhibited renal 11β-HSD2 activity in rats in a dose-dependent manner [59,60]. Kato et al. [61] suggested that 3MGA, not GA, is the mainly causative agent of licorice-induced pseudohyperaldosteronism. In the kidneys, 11β-HSD2 inhibition by 3MGA or GA (Kᵢ: 5–10 nM) results in a significant increase of active cortisol concentration in the renal tissue leading to a syndrome of apparent mineralocorticoid excess (Figure 3a) [52,62]. In the vascular wall, it increases arterial tone enhancing contractile responses to pressor hormones and reducing endothelial nitric oxide production [57,63]. Further animal studies reported a markedly inhibitory effect of GA on hepatic ring A-reduction of aldosterone by two other hepatic enzymes (5β-reductase and 3β-hydroxysteroid dehydrogenase), increasing the circulating aldosterone levels [64].
Figure 3. (a) Correlation between licorice intake, the renin-angiotensin-aldosterone-system and licorice-induced adverse effects on the cardiovascular system. (b) Detailed pharmacodynamics of 3β-monoglucuronyl-18β-glycyrrhetinic acid (3MGA) and 18β-glycyrrhetinic acid (GA; blue structure) in the kidney. In addition to a possible direct binding to the mineralocorticoid receptor (MR), 3MGA and GA have inhibiting effects on 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) and 5β-reductase. 11β-HSD2 converts cortisol to cortisone; 5β-reductase is involved in the degradation of aldosterone in the liver. Inhibition of both enzymes contributes to apparent mineralocorticoid excess. The insert shows the localization of the processes within the Henle loop. ACE: angiotensin converting enzyme, ENaC: epithelial sodium channel, ET-1: endothelin 1, HRE: hormone response element, NAD(H): nicotinamide adenine dinucleotide, NO: nitric oxide, ROMK: renal outer medullary potassium channel. Parts of the figure were drawn by using pictures from Servier Medical Art (http://smart.servier.com), licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0).
A vasorelaxant effect of glabridin was described in rat mesenteric arteries, which was associated with the opening of potassium channels and a concomitant rise in tissue cyclic guanosine monophosphate levels [65].

Taken together, intake of licorice induces a mild form of apparent mineralocorticoid excess causing MRs to be activated by both cortisol and aldosterone via inhibition of enzymes necessary for their catabolism (Figure 3). The direct effects of 3MGA and GA on MRs seem to be only negligible in physiological conditions. In the kidney, MR activation leads to transcription of epithelial sodium channel (ENaC), Na+/K+ ATPase and mitochondrial enzymes, which accelerate adenosine triphosphate (ATP)-production (Figure 3b). The final consequences comprise elevated BP, sodium and water retention, decreased plasma potassium (hypokalemia) and caused a suppression of plasma renin and aldosterone levels [66]. In vascular smooth muscle cells, MR activation may further cause vascular stiffening by remodeling of the vascular wall [67]. Furthermore, direct effects of MR activation were described for the rat heart [68].

2.3. Licorice-Induced Hypertension

Licorice mediates its effect on BP primarily via the inhibition of renal 11β-HSD2 by 3MGA and GA (Figure 3a). Water and sodium retention in the kidney increase the blood volume and elevate BP [5]. The body countermeasures with a refractory lowering of the renin secretion in the kidneys, followed by decreased aldosterone production in the adrenal cortex via angiotensin II. However, the increasing level of cortisol (together with unrestricted activation of MR by cortisol) causes pseudohyperaldosteronism. This in turn results in further increasing blood volume and preload of the heart, thereby raising the mean arterial pressure. Furthermore, GA mediates the development of hypertension via decreased bioavailability of NO and activation of the vascular endothelin (ET-1) system (Figure 3a) which was accompanied by impaired endothelium-dependent relaxation in rats [69]. Activation of the endothelin system was also observed in human hypertension [70], and there is some evidence that increased ET-1 may be related to hypertensive end-organ damage and remodeling [71]. Interestingly, an infusion of GA into the rat brain elevated BP without affecting renal sodium and water resorption [72]. This finding indicated a central hypertensinogenic effect of licorice and suggested a more complex regulation of licorice-induced hypertension beyond the inhibition of 11β-HSD2.

Since a correlation between licorice ingestion and BP looks undeniable, further evaluation of quantities is necessary. Leskinen et al. [28] found that a daily intake of 290–370 mg licorice elevated both systolic and diastolic BP after two weeks. Furthermore, an increase of the extracellular fluid volume (hypervolemia) and amplified pressure wave reflection from the peripheral circulation was reported. Hautaniemi et al. [73] demonstrated that in addition to extracellular volume expansion, licorice increased stiffness of large arteries and systemic vascular resistance. A linear dose-response relationship between licorice intake and elevated BP was first proposed by Sigurjonsdottir et al. [27], who found that a daily ingestion of 75 mg GA (~50 g of licorice) was sufficient to cause a significant increase in systolic BP within a period of two weeks. Similar correlations were later reported by a meta-analysis: analyzing the data of 18 studies (337 patients), systolic and diastolic BP seem to rise dose-dependently suggesting a public recommendation of avoiding excessive licorice consumption [74]. Based on the results of a 12-week experiment with 39 healthy female volunteers, van Gelderen et al. [75] proposed a no-effect level of 2 mg/kg GA per day (equal to 6 g licorice for a person with a body weight of 60 kg).
Two questions remain: 1. Is there any evidence that licorice will increase BP in patients dealing with hypotension? 2. Can general practitioners advocate the complementation of a normal diet with an intake of black licorice or other products containing GA in hypotensive patients? In 1994, it was reported that a 63-year old type 2 diabetic patient was treated for postural hypotension using licorice (3 g of GA/day) as treatment [76]. The patient’s BP increased from 90/60 mmHg to 130/80 mmHg in an upright position in 7 days of therapy. Thus, there might be some indications that licorice has its place in clinical therapy, but this must be further investigated in a double-blind, randomized, place-controlled trial to avoid bias.

The case reports of licorice-induced hypertension found in the literature range from mild and reversible forms to severe resistant hypertension requiring hospitalization. In consequence of the elevated BP some patients developed hypertensive encephalopathy or cerebrovascular accidents [77–79]. Acute heart failure, pulmonary edema [80–82] or generalized edema [83–85] can be caused by the sodium retaining effect of licorice (Figure 3a). Interestingly, the occurrence of edema associated with hypertension seems to be characteristic for the ‘licorice syndrome’. This is in contrast to true mineralocorticoid excess, where edema is typically absent as a result of the “sodium escape” phenomenon [86,87]. An observed increase in plasma concentration of atrial natriuretic peptide (ANP) after long-term consumption of licorice may be considered a physiological, albeit ineffective, response to prevent fluid retention and development of hypertension [88].

The effects of licorice on aldosterone secretion differ between the genders independently of the BP levels; women seem to be more susceptible to licorice intake [89,90]. A possible explanation for this gender difference are many other hormonal (estrogenic and antiandrogenic) effects exhibited by licorice in addition to its activity via MR. At least the alterations of the calcium metabolism that were observed in healthy women in response to licorice are probably influenced by several further components of the root such as glabridin, which shows estrogen-like activity [89].

There is very rare and controversial information about the correlation between licorice and the development of pulmonary hypertension. A possible contribution of licorice to pulmonary hypertension was suggested by Ruszymah et al. [91] after they had observed an increase in right atrial pressure and thickening of the pulmonary vessels of rats after GA administration. On the other hand, Yang et al. [92] described the attenuation of pulmonary hypertension progression and pulmonary vascular remodeling by glycyrrhizin in a monocrotaline-induced pulmonary hypertension rat model. Here, further studies are needed.

2.3.1. Meta-analyses of Human Trials

In 2017, Penninkilampi et al. [74] reviewed the association between licorice intake, hypertension and hypokalemia. In a broad-based meta-analysis, they confirmed a significant increase in both systolic (5.45 mmHg; 95% confidence interval (CI) 3.51–7.39) and diastolic BP (3.19 mmHg; 95% CI 0.10–6.29) after chronic intake of products containing GA. Since physiological effects are not directly induced by licorice but rather by GA, the GA consumption was calculated for most of the studies. A GA content of 0.2% was approximated for black licorice [74] although the concentration of GA can obviously vary from product to product. Thus, the mean intake of 377.9 mg GA is equal to 189 g of licorice [74] and accounts for the described increase in systolic and diastolic BP. A further meta- and trial sequential analysis by Luis et al. [87] (26 trials, 985 patients) confirmed the significant increase in diastolic BP (1.74 mmHg; 95% CI 0.83–2.62) associated with the hypernatremia caused by licorice consumption. As mentioned by Penninkilampi et al. [74], most of the trials included in their meta-analysis were performed with volunteers. Selection bias in using volunteers and not random participants might be limiting results. The authors found that patients had higher increases in BP after a long intake of GA. They stratified the data in <4 weeks and ≥4 weeks and got elevations of 7.83 mmHg (95% CI 3.69–11.98) and 4.44 mmHg (95% CI 3.20–5.68), respectively. This confirmed the dose-response relationship and a positive correlation between GA dose and changes in both systolic and diastolic BP [74]. The significant increase of 5.45 mmHg might not cause adverse effects in a healthy
individual. However, combined with hypokalemia, it can lead to problems in individuals dealing with uncontrolled hypertension [74]. There have been case reports of patients with hypertensive crises where high licorice-intake in combination with hypertension caused hospitalization [93]. Compared with the modest results found in the meta-analysis on the available literature, the number of case reports with serious events or death after chronic licorice ingestion appears excessive [74]. A history of high licorice consumption alone is mostly sufficient to induce a toxic state. The degree of hypokalemia can be severe to cause a lethal arrhythmia [5].

2.3.2. Treatment

In most cases, hypertension and hypervolemia induced by licorice is reversible once intake is stopped. If treatment of licorice-induced hypertension should be necessary, patients will usually be treated as normal hypertensive patients with antihypertensive therapy [94]. Different biochemical analyses will indicate a state of hyperaldosteronism by displaying low plasma potassium and lower levels of plasma renin and aldosterone. Antihypertensive therapy that targets the MR, such as spironolactone, seems to be the primary choice [69]. In rats, it was shown that blocking MR normalized BP [69]. Spironolactone works as a competitive aldosterone antagonist reducing the number of ENaC and Na⁺/K⁺-ATPase in reverse to aldosterone and cortisol. However, spironolactone treatment is only suggested for an acute hypertensive crisis. Lifestyle interventions should be advised against chronic hypertension caused by high ingestion of licorice and GA-containing products. Depending on the severity, either less ingestion of licorice or a complete stop will be necessary. The ESC guidelines state that grade 2 or 3 hypertension have to be treated with antihypertensive therapy [32]. This accounts for a clinically measured systolic BP ≥ 160 mmHg and/or a diastolic BP ≥ 100 mmHg. Since the effects on electrolyte-levels are delayed, it is furthermore important to stabilize electrolytes, with specific focus of on potassium. When licorice-induced hypertension is treated, it should be kept in mind that it can take up to six months to reverse the mineralocorticoid-like effects of licorice due to its long half-life and the duration required to normalize the renin-angiotensin-aldosterone-system [95].

Indeed, the ESC guidelines for treating hypertension mention that the intake of licorice could influence BP. They address that the medical history should include use of licorice [32]. However, there are no further comments on how licorice-induced hypertension should be treated. An intervention study aimed to investigate whether hypertensive patients were more sensitive to the inhibition of 11\(\beta\)-HSD2 than normotensive patients [96] and found that after 4 weeks of licorice consumption, the mean increase in systolic BP was 3.5 mmHg in healthy individuals and 15.3 mmHg in hypertensive subjects. The mean rise in diastolic BP confirmed this with an increase of 3.6 in mmHg in normotensive and 9.3 mmHg in hypertensive patients. The \(p\)-value showed significant differences in both systolic (\(p = 0.004\)) and diastolic BP (\(p = 0.03\)) [96]. Thus, the authors concluded that subjects with essential hypertension are more sensitive to the licorice-induced inhibition of 11\(\beta\)-HSD2 than normotensive subjects. This finding supports the suggestion that licorice might have stronger adverse effects in patients suffering from hypertension.

However, the available data on this topic is limited and of modest quality and only one clinical trial can be found (Table 1). Further double-blind randomized placebo-controlled studies would be necessary to determine the clinical effects of licorice intake in both healthy and non-healthy individuals.
Table 1. Studies investigating the effects of licorice intake on the human cardiovascular system.

| Author (Year), Country | Study Design | n  | Drug            | Daily Dose | Duration | Relevant Results                                                                 |
|------------------------|--------------|----|-----------------|------------|----------|----------------------------------------------------------------------------------|
| Epstein et al. (1977)  | Pre-post intervention | 14 | Licorice        | 100-200 g  | 1-4 weeks | Serious metabolic effects due to modest licorice intake.                          |
| Forslund et al. (1989) | Pre-post intervention | 15 | Licorice        | 100 g      | 8 weeks   | Increase in plasma ANP, Decrease in antidiuretic hormone, aldosterone, and plasma renin activity. |
| MacKenzie et al. (1990) | Pre-post intervention | 10 | GA              | 500 mg     | 8 days    | Inhibition of 11β-HSD2.                                                           |
| Kageyama et al. (1992) | Pre-post intervention | 58 | Glycyrrhizin    | 225 mg     | 7 days    | Changes in cortisol metabolism.                                                   |
| Bernadini (1994)      | Pre-post intervention |    | Licorice root   | 108-814 mg glycyrrhizin | 14 days | Depression of plasma renin activity favored by subclinical disease.               |
| Armanini et al. (1996) | Pre-post intervention | 6  | Licorice        | 7 g (500 mg GA) | 7 days | Decreased activity of 11β-HSD2.                                                   |
| van Gelderen et al. (2000) | Double-blind randomized controlled | 39 | GA              | 0-4 mg per kg | 8 weeks | No-effect level: 2 mg/kg GA per day.                                              |
| Sigurjónsdóttir et al. (2001) | Pre-post intervention | 24 | Licorice        | 50-200 g   | 2-4 weeks | Increase in SBP.                                                                 |
| Sigurjónsdóttir et al. (2003) | Pre-post intervention | 25 | Licorice        | 100 g      | 4 weeks   | Increase in SBP and DBP. Subjects with essential hypertension are more sensitive to licorice-induced rise in BP. |
| Sigurjónsdóttir et al. (2006) | Pre-post intervention | 25 | Licorice        | 100 g      | 4 weeks   | The effect on aldosterone secretion differs between the genders.                 |
| Sobieszczky et al. (2010) | Randomized double-blind placebo-controlled crossover | 15 | GA              | 130 mg     | 14 days   | Attenuated vasodilatory function on VSMCs.                                       |
| Tu et al. (2010)      | Two-phase randomized crossover | 16 | Glycyrrhizin    | 2 x 150 mg | 14 days   | Induction of CYP3A.                                                             |
| Yan et al. (2013)     | Two-phase randomized crossover | 14 | Glycyrrhizin (salt tablet) | 3 x 75 mg | 6 days    | No induction of P-glycoprotein.                                                  |
| Leksmen et al. (2014) | Non-randomized, controlled open label | 20 | Licorice        | 290-370 mg glycyrrhizin | 14 days | Increase in SBP, DBP, extracellular volume and amplified pressure wave reflection from the periphery. |
| Hautaniemi et al. (2017) | Non-randomized, controlled open label | 22 | Licorice        | 290-370 mg glycyrrhizin | 14 days | Increase in SBP, DBP, central pulse pressure, extracellular fluid volume and aortic to popliteal pulse wave velocity. |

11β-HSD2: 11-β-hydrogenase type II enzyme; ANP: atrial natriuretic peptide; BP: blood pressure; CYP3A: cytochrome P450 3A4; DBP: diastolic blood pressure; GA: 18β-glycyrrhetinic acid; SBP: systolic blood pressure; VSMC: vascular smooth muscle cell.

2.4. Cardiovascular Effects of Licorice

Licorice traditionally has been prescribed for treatment of cardiovascular disorders, but its effects are not just benign. From the cardiovascular complication described in the literature, cardiac arrhythmias are the most serious side effect caused by licorice intake due to severe hypokalemia (Figure 3a) [105]. The depletion of the body’s potassium stores can cause a prolongation of the QT interval, which is closely connected with ventricular arrhythmias and tachycardia [106]. As a consequence, several patients experienced a cardiac arrest with a subsequent recovery [107–109]. Konik et al. [110] described a case of coronary artery spasm induced by licorice. The vasospastic effect of licorice was attributed to changes in endothelin and nitric oxide systems. Recently, a Polish clinical study found a correlation of arterial stiffness parameters with estimated cardiovascular risks in humans [111]. Transient visual loss, migraines and posterior reversible encephalopathy syndrome has also been demonstrated in a few cases. It is assumed that GA inhibits angiogenesis due to inhibition of reactive oxygen species generation [112]. Sobieszczky et al. [102] found an additional attenuated vascular smooth muscle vasodilatory function without BP changes in healthy humans after 11β-HSD2 inhibition through GA. They proposed that in states of 11β-HSD2 inactivation,
non-aldosterone-mediated activation of vascular MRs may contribute to vascular dysfunction and possibly to CVDs.

In rats, cardioprotective effects of licorice and its metabolites were observed, which are mostly related to their antioxidant properties. Thirty days of licorice intake improved cardiac function and preserved histology of cardiomyocytes either by augmentation of endogenous antioxidants or by reduction in oxidative stress. Thus, licorice may delay the progression of ischemic heart disease [113]. Ohja et al. [114] further described a cardioprotective effect against oxidative stress in myocardial ischemia-reperfusion injury after ingestion of Glycyrrhiza glabra. Another animal study indicated that GA protects against isoproterenol-induced oxidative stress in rat myocardium decreasing lipid hydroperoxides and isoprostanes and increasing superoxide dismutase and glutathione levels [115].

Some studies suggested that the flavonoid glabridin may also have beneficial effects on the cardiovascular system. The effects described comprise inhibition of low density lipoprotein oxidation and atherogenesis [116], a possible inhibition of NADPH oxidase or an increase in the expression of antioxidant enzymes observed in macrophages [117]. Glabridin also stimulates DNA synthesis in human endothelial cells and demonstrated a bi-phasic proliferative effect on human vascular smooth muscle cells. The combination of an inhibition of smooth muscle cell proliferation and an induction of endothelial cell proliferation may be beneficial for the prevention of atherosclerosis [118,119]. Most recently, Huang et al. [120] reported that glabridin is able to prevent doxycyclin-induced cardiotoxicity in mice through the prevention of gut microbiota dysbiosis. Nevertheless, it remains unclear to which extent these effects contribute to the putative therapeutic actions of licorice.

2.5. Interaction of Licorice with Prescribed Drugs

Licorice can interfere with cardiac medications, e.g., with drugs used in the treatment of hypertension such as angiotensin converting enzyme (ACE)-inhibitors [121]. Some licorice compounds including glabridin and GA can interact with other drugs and the human liver microsomal cytochromes P450 and P450 3A4 (CYP3A4) systems [122–125]. Animal [126,127] and human studies [103] showed that glycyrrhizin has an inductive effect on CYP3A including CYP3A4 and the effect on CYP3A4 may be related to an activation of human pregnane X receptor (hPXR) [103,128]. Other studies described that CYP3A4 was inactivated by licorice extract and glabridin in a time- and concentration-dependent manner [124]. CYP3A4 is involved in the metabolism of xenobiotics [122], roughly half the drugs that are in use today, suggesting that the influence of licorice on CYP3A4 activity needs to be further investigated.

Heck et al. [129] described a toxic effect potentiation of warfarin, a cardiac drug that requires strict dosage adjustment, due to the inhibition of the hepatic microsomal enzymes by licorice.

Matsumoto et al. [130] investigated the effects of licorice on ABC-transporters. Using an in vivo ATPase assay, they demonstrated that licorice root and GA can inhibit P-glycoprotein. A two-phase randomized crossover trial by Yan et al. [104] revealed at least no induction effect on the P-glycoprotein expression after continuous glycyrrhizin administration (225 mg/day) for 6 days. The authors proposed that further research was needed to study the direct inhibition effect of glycyrrhizin on P-glycoprotein. For the pharmaceutical use, it is important to know and consider the interaction between licorice and drugs metabolized by CYP3A4 and P-glycoprotein.

Licorice decreases the bioavailability of cyclosporine and is thus contraindicated [120] in conjunction with this drug [128]. The intake of licorice should be done with caution, when using antihypertensive drugs. ACE-inhibitors, e.g., captopril, inhibit the angiotensin converting enzyme, limiting levels of angiotensin and aldosterone. It was shown that ACE-inhibitors enhance the effects of 11β-HSD2 which may contribute to the natriuretic effect [131]. Hypokalemia is one of the most serious adverse effects of licorice intake and should be completely avoided with loop-diuretics and thiazides since it can lead to serious hypokalemia and hospitalization [132].
The combination of medicine containing licorice and digitalis can cause toxicity, especially in elderly patients. There has been one reported case of digoxin toxicity due to licorice-induced hypokalemia [133].

2.6. Contraindications and Effects of Licorice Overconsumption

Licorice and its derivatives are affirmed as ‘Generally Recognized as Safe’ (GRAS) for use in foods by the United States Food and Drug Administration (21 CFR 184.1408). Nevertheless, tolerable upper limits of licorice intake have been provided by several institutions: the European Scientific committee of Food recommends that the daily ingestion should not exceed 100 mg of glycyrrhizin (60–70 g of licorice) [134]; the Dutch Nutrition Information Bureau advised against a daily consumption above 200 mg of glycyrrhizin (150 g of licorice) [2]. Since most consumers are not aware of possible health hazards, and there are currently no precise declaration data of glycyrrhizin on food, it is difficult to control licorice intake. Furthermore, it has to be investigated if sporadic intake carries the same risks compared to the daily consumption that is analyzed in most studies. Licorice is found in diet gum, cough mixtures, tea and herbal medicine. Having a mixed intake of these products will accumulate the quantity of GA in vivo, and therefore, increase the risk of symptoms.

In general, people aged over 40, patients with history of cardiac disease or more susceptible to cardiac arrhythmias should avoid excess licorice intake in order to obviate arrhythmias or cardiac arrest caused by licorice-induced hypokalemia. One study investigated patients treated with traditional Japanese medicine containing licorice [135]. They discovered that 24.2% of the patients treated with this medicine developed hypokalemia 34 days after administration. Hypokalemia is a serious state that increases the risk of arrhythmia and is associated with an up to 10-time increase in all-cause mortality [74]. The meta-analysis by Penninkilampi et al. [74] summarized other side effects including rhabdomyolysis, paralysis, hypertensive encephalopathy and cardiac arrest. That is why patients who are on medicines lowering potassium levels (such as thiazide or loop diuretics) should also minimize their licorice intake. The same applies for patients suffering from diarrhea or alcoholism, which can worsen hypokalemia. Licorice can be dangerous in patients treated with antihypertensive drugs such as ACE-inhibitors and diuretics. Due to the salt-retaining effect of 3MGA and GA, people suffering from congestive heart failure or resistant hypertension should completely abstain from products containing licorice. This is also advisable for patients taking digoxin or warfarin to avoid the risk of toxicity. Since 3MGA and GA are known to inhibit 11β-HSD2, licorice ingestion during pregnancy should be avoided. GA consumption impaired the development of the respiratory systems in rats because the conversion of cortisone into cortisol plays an important role in lung maturation [136].

3. Conclusions

In recent years, the mechanisms of action of licorice and its active components have become understood in more detail. The use of licorice in herbal medicine is obviously a result of some positive effects. Hence, it has become one of the most used herbs in traditional Chinese medicine and is still used in China to treat gastric symptoms and respiratory diseases today [10]. Numerous studies have reported about effects of the different compounds found in the licorice root. Glabridin has been proven to be a potent antioxidant with hypoglycemic effects [21]. Referring to studies, glycyrrhizin possesses a wide range of pharmacological effects described as antiulcer and anti-inflammatory [11–13], antiviral [14,15], anticariogenic [137,138] and antispasmodic [139,140].

The utilization of some licorice compounds in a clinical setting is still under investigation. This applies also for artificial GA derivatives such as carbenoxolone [141] or acetoxolone [142]. Glycyrrhizin was identified as an attractive drug candidate for cancer therapy after demonstrating an apoptotic effect on tumor cells [143]. Today, researchers are intensely investigating the applicability of licorice in treatment of breast and prostate cancer. The antitumor activity has attracted the attention of many scientists, since cancer is still one of the leading causes of death in humans around the globe [10].
Nevertheless, due to some safety considerations associated with chronic high-dose intake, licorice should still be consumed with caution. With the elucidation of licorice constituents and the discovery that 3MGA and GA affect the renin-angiotensin-aldosterone-system, pseudohyperaldosteronism is the obvious adverse effect; however, other side effects such as hypertension, hypokalemia and hypernatremia have also been proven. If left untreated, they can cause arrhythmia and, in a worst-case scenario, cardiac arrest. Omar et al. [30,40] have described in detail why licorice should be handled more as medicine than as a candy and that excess licorice consumption can cause serious life-threatening complications, especially in individuals already dealing with high BP and patients under treatment with anti-hypertensive drugs. Adverse effects of high-dose licorice intake have been attributed to glycyrrhizin, 3MGA and GA. Since the final toxicology report has been published in 2007, therapeutic doses of licorice are generally recommended as safe in humans [144]. Especially Scandinavian countries have a higher intake of licorice, and in addition, their licorice has a higher GA concentration [121]. This suggests a need of public focus on the negative effects of licorice on cardiovascular health. However, this is also needed in China, where licorice is widely used in medical practice; here, the knowledge of licorice’s interaction with prescription medicines is quite important to avoid possible iatrogenic accidents.

Author Contributions: Conceptualization, M.R.D., D.G. and M.K.; methodology, M.R.D.; validation, D.G., M.W. and M.K.; investigation, M.R.D.; resources, M.I.; data curation, D.G. and M.K.; writing—original draft preparation, M.K., M.R.D. and D.G.; writing—review and editing, M.K., D.G. and M.W.; visualization, M.K.; supervision, D.G.

Funding: This research received no external funding.

Acknowledgments: The authors would like to thank Walter Welß (Botanical Garden of Erlangen) for kindly providing photos of Glycyrrhiza glabra.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

11β-HSD2 11-β-hydrogenase type II enzyme
3MGA 3β-monoglucuronyl-18β-glycyrrhetinic acid
ACE Angiotensin converting enzyme
ANP Atrial natriuretic peptide
ATP Adenosine triphosphate
BP Blood pressure
CI Confidence interval
CVD Cardiovascular disease
CYP3A4 Cytochrome P450 3A4
DBP Diastolic blood pressure
ENaC Epithelial sodium channel
ESC European Society of Cardiology
ET-1 Endothelin 1
GA 18β-glycyrrhetinic acid
HRE Hormone response element
MR Mineralocorticoid receptor
NAD(H) Nicotinamide adenine dinucleotide
NO Nitric oxide
ROMK Renal outer medullary potassium channel
SBP Systolic blood pressure
VSMC Vascular smooth muscle cell
References

1. Foster, C.A.; Church, K.S.; Poddar, M.; Van Uum, S.H.; Spaic, T. Licorice-induced hypertension: A case of pseudohyperaldosteronism due to jelly bean ingestion. *Postgrad. Med.* 2017, 129, 3293–3331. [CrossRef] [PubMed]

2. Fenwick, G.R.; Lutomski, J.; Nieman, C. Licorice, *Glycyrrhiza glabra* L.—Composition, uses and analysis. *Food Chem.* 1990, 38, 1191–1243. [CrossRef]

3. Kao, T.C.; Wu, C.H.; Yen, G.C. Bioactivity and potential health benefits of licorice. *J. Agric. Food Chem.* 2014, 62, 542–553. [CrossRef] [PubMed]

4. Fiore, C.; Eisenhut, M.; Ragazzi, E.; Zanchin, G.; Armanini, D. A history of the therapeutic use of liquorice in Europe. *J. Ethnopharmacol.* 2005, 99, 317–324. [CrossRef]

5. Isbrucker, R.A.; Burdock, G.A. Risk and safety assessment on the consumption of licorice root (*Glycyrrhiza* sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. *Regul. Toxicol. Pharmacol.* 2006, 46, 167–192. [CrossRef]

6. NCCIH. Licorice Root. Available online: [http://nccih.nih.gov/health/licoricercroot](http://nccih.nih.gov/health/licoricercroot) (accessed on 24 September 2019).

7. Volqvartz, T.; Vestergaard, A.L.; Andreasen, M.F.; Lesnikova, I.; Uldbjerg, N.; Larsen, A.; Bor, P. Use of alternative medicine, ginger and licorice among Danish pregnant women—A prospective cohort study. *BMC Complement. Altern. Med.* 2019, 19, 5. [CrossRef]

8. Yang, R.; Wang, L.Q.; Yuan, B.C.; Liu, Y. The pharmacological activities of licorice. *Planta Med.* 2015, 81, 1654–1669. [CrossRef]

9. Aly, A.M.; Al-Alousi, L.; Salem, H.A. Licorice: A possible anti-inflammatory and anti-ulcer drug. *AAPS PharmSciTech* 2005, 6, E74–E82. [CrossRef]

10. Jalilzadeh-Amin, G.; Najarnezhad, V.; Anassori, E.; Mostafavi, M.; Keshiopour, H. Antiulcer properties of *Glycyrrhiza glabra* L. Extract on experimental models of gastric ulcer in mice. *Iranian J. Pharm. Res.* 2015, 14, 1163–1170.

11. Yang, R.; Yuan, B.C.; Ma, Y.S.; Zhou, S.; Liu, Y. The anti-inflammatory activity of licorice, a widely used Chinese herb. *Pharm. Biol.* 2017, 55, 5–18. [CrossRef] [PubMed]

12. Fang, L.; Yang, R.; Yuan, B.; Liu, Y.; Liu, C. The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb. *Acta Pharm. Sin. B* 2015, 5, 310–315. [CrossRef] [PubMed]

13. Fukuchi, K.; Okudaira, N.; Adachi, K.; Odai-Ido, R.; Watanabe, S.; Ohno, H.; Yamamoto, M.; Kanamoto, T.; Terakubo, S.; Nakashima, H.; et al. Antiviral and antitumor activity of licorice root extracts. *In Vivo* 2016, 30, 777–785. [CrossRef]

14. Huo, H.Z.; Wang, B.; Liang, Y.K.; Bao, Y.Y.; Gu, Y. Hepatoprotective and antioxidant effects of licorice extract against CCl4-induced oxidative damage in rats. *Int. J. Mol. Sci.* 2011, 12, 6529–6543. [CrossRef]

15. Jung, J.-C.; Lee, Y.-H.; Kim, S.H.; Kim, K.-J.; Kim, K.-M.; Oh, S.; Jung, Y.-S. Hepatoprotective effect of licorice, the root of Glycyrrhiza uralensis Fischer, in alcohol-induced fatty liver disease. *BMC Complement. Altern. Med.* 2016, 16, 19. [CrossRef]

16. Wang, Z.Y.; Nixon, D.W. Licorice and cancer. *Nutr. Cancer* 2001, 39, 1–11. [CrossRef]

17. Momani, A.; Rahman, G.; Kiasi, A.; Amiri, M.; Kheir, S. Effect of licorice versus bismuth on eradication of Helicobacter pylori in patients with peptic ulcer disease. *Pharmacogn. Res.* 2014, 6, 341–344. [CrossRef]

18. Wu, F.; Jin, Z.; Jin, J. Hypoglycemic effects of glabridin, a polyphenolic flavonoid from licorice, in an animal model of diabetes mellitus. *Mol. Med. Rep.* 2013, 7, 1278–1282. [CrossRef]

19. Simmler, C.; Pauli, G.F.; Chen, S.N. Phytochemistry and biological properties of glabridin. *Fitoterapia* 2013, 90, 160–184. [CrossRef] [PubMed]
23. Stepien, M.; Kujawska-Luczak, M.; Szulinska, M.; Kregielska-Narozna, M.; Skrypnik, D.; Suliburska, J.; Skrypnik, K.; Regula, J.; Bogdanski, P. Beneficial dose-independent influence of *Camellia sinensis* supplementation on lipid profile, glycemia, and insulin resistance in an NaCl-induced hypertensive rat model. *J. Physiol. Pharmacol.* 2018. [CrossRef]

24. Sontia, B.; Mooney, J.; Gaudet, L.; Touyz, R.M. Pseudohyperaldosteronism, liquorice, and hypertension. *J. Clin. Hypertens.* 2008, 10, 153–157. [CrossRef]

25. Varma, R.; Ross, C.N. Liquorice: A root cause of secondary hypertension. *JRSM Open* 2017, 8, 2054270416685208. [CrossRef] [PubMed]

26. Morris, D.J. Liquorice: New insights into mineralocorticoid and glucocorticoid hypertension. *R. I. Med.* 1993, 76, 251–254.

27. Sigurjónsdóttir, H.Á.; Franzson, L.; Manhem, K.; Ragnarsson, J.; Sigurdsson, G.; Wallerstedt, S. Liquorice-induced rise in blood pressure: A linear dose-response relationship. *J. Hum. Hypertens.* 2001, 15, 549–552. [CrossRef]

28. Leskinen, M.H.; Hautaniemi, E.J.; Tahvanainen, A.M.; Koskela, J.K.; Päälyssaho, M.; Tikkakoski, A.J.; Kähönen, M.; Kööbi, T.; Niemelä, O.; Mustonen, J.; et al. Daily liquorice consumption for two weeks increases augmentation index and central systolic and diastolic blood pressure. *PLoS ONE* 2014, 9, e105607. [CrossRef]

29. Falet, J.P.; Elkrief, A.; Green, L. Hypertensive emergency induced by licorice tea. *CMAJ* 2019, 191, E581–E583. [CrossRef]

30. Omar, H.R. The cardiovascular complications of licorice. *Cardiovasc. Endocrinol.* 2013, 2, 46–49. [CrossRef]

31. Forouzanfar, M.H.; Liu, P.; Roth, G.A.; Ng, M.; Biryukov, S.; Marczak, L.; Alexander, L.; Estep, K.; Hassen Abate, K.; Akinyemiju, T.F.; et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm hg, 1990–2015. *JAMA* 2017, 317, 165–182. [CrossRef]

32. Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.; de Simone, G.; Dominiczak, A.; et al. 2018 esc/esh guidelines for the management of arterial hypertension. *Eur. Heart J.* 2018, 39, 3021–3104. [CrossRef] [PubMed]

33. Charles, L.; Triscott, J.; Dobbs, B. Secondary hypertension: Discovering the underlying cause. *Am. Fam. Phys.* 2017, 96, 453–461.

34. Wang, Q.; Qian, Y.; Wang, Q.; Yang, Y.F.; Ji, S.; Song, W.; Qiao, X.; Guo, D.A.; Liang, H.; Ye, M. Metabolites identification of bioactive licorice compounds in rats. *J. Pharm. Biomed. Anal.* 2015, 115, 515–522. [CrossRef] [PubMed]

35. Nieman, C. Licorice. *Adv. Food Res.* 1957, 7, 339–381.

36. Kim, D.-H.; Lee, S.-W.; Han, M.J. Biotransformation of glycyrrhizin to 18β-glycyrrhetinic acid-3-O-β-d-glucuronide by streptococcus lj-22, a human intestinal bacterium. *Biol. Pharm. Bull.* 1999, 22, 320–322. [CrossRef]

37. Hattori, M.; Sakamoto, T.; Yamagishi, T.; Sakamoto, K.; Konishi, K.; Kobashi, K.; Namba, T. Metabolism of glycyrrhizin by human intestinal flora. II. Isolation and characterization of human intestinal bacteria capable of metabolizing glycyrrhizin and related compounds. *Chem. Pharm Bull.* 1985, 33, 210–217. [CrossRef]

38. Armanini, D.; Nacamulli, D.; Francini-Pesenti, F.; Batta, G.; Ragazzi, E.; Fiore, C. Glycyrrhetinic acid, the active principle of licorice, can reduce the thickness of subcutaneous thigh fat through topical application. *Steroids* 2005, 70, 538–542. [CrossRef]

39. Feng, X.; Ding, L.; Qiu, F. Potential drug interactions associated with glycyrrhizin and glycyrrhetinic acid. *Drug Metab. Res.* 2015, 47, 229–238. [CrossRef]

40. Omar, H.R.; Komarova, I.; El-Ghonemi, M.; Fathy, A.; Rashad, R.; Abdelmalak, H.D.; Yerramadha, M.R.; Ali, Y.; Helal, E.; Camporesi, E.M. Licorice abuse: Time to send a warning message. *Ther. Adv. Endocrinol.* 2012, 3, 125–138. [CrossRef]

41. Ploeger, B.; Mensinga, T.; Sips, A.; Meulenbelt, J.; Defonj, J. A human physiologically-based model for glycyrrhizic acid, a compound subject to presystemic metabolism and enterohepatic cycling. *Pharm. Res.* 2000, 17, 1516–1525. [CrossRef]

42. Cao, J.; Chen, X.; Liang, J.; Yu, X.Q.; Xu, A.L.; Chan, E.; Wei, D.; Huang, M.; Wen, J.Y.; Yu, X.Y.; et al. Role of p-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of glycyrrhiza glabra. *Drug Metab. Dispos.* 2007, 35, 539–553. [CrossRef]
43. Ito, C.; Oi, N.; Hashimoto, T.; Nakabayashi, H.; Aoki, F.; Tominaga, Y.; Yokota, S.; Hosoe, K.; Kanazawa, K. Absorption of dietary licorice isoflavon glabridin to blood circulation in rats. J. Nutr. Sci. Vitaminol. 2007, 53, 358–365. [CrossRef]

44. Aoki, F.; Nakagawa, K.; Tanaka, A.; Matsuzaki, K.; Arai, N.; Mae, T. Determination of glabridin in human plasma by solid-phase extraction and lc-ms/ms. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 828, 70–74. [CrossRef] [PubMed]

45. Raggi, M.A.; Maffei, F.; Bugamelli, F.; Cantelli Forti, G. Bioavailability of glycyrrhizin and licorice extract in rat and human plasma as detected by a hplc method. Pharmazie 1994, 49, 269–272.

46. Cantelli-Forti, G.; Maffei, F.; Hrelia, P.; Bugamelli, F.; Bernardi, M.; D’Intino, P.; Maranesi, M.; Raggi, M.A. Interaction of licorice on glycyrrhizin pharmacokinetics. Environ. Health Perspect. 1994, 102 (Suppl. 9), 65–68. [CrossRef]

47. Ishiuchi, K.; Morinaga, O.; Ohkita, T.; Tian, C.; Hirasawa, A.; Mitamura, M.; Maki, Y.; Kondo, T.; Yasujima, T.; Yuasa, H.; et al. 18beta-glycyrrhetin 3-o-sulfate would be a causative agent of licorice-induced pseudoaldosteronism. J. Steroid Biochem. Mol. Biol. 2004, 89, 1973–1976. [CrossRef]

48. Morinaga, O.; Ishiuchi, K.; Ohkita, T.; Tian, C.; Hirasawa, A.; Mitamura, M.; Maki, Y.; Yasujima, T.; Yuasa, H.; Makino, T. Isolation of a novel glycyrrhetinic acid as a causal candidate compound for pseudoaldosteronism. Sci. Rep. 2018, 8, 15568. [CrossRef]

49. Armanini, D.; Karbowiak, I.; Funder, J.W. Affinity of licorice derivatives for mineralocorticoid and glucocorticoid receptors. Clin. Endocrinol. 1983, 19, 609–612. [CrossRef] [PubMed]

50. Calo, L.A.; Zaghetto, F.; Pagnin, E.; Davis, P.A.; De Mozzi, P.; Sartorato, P.; Martire, G.; Fiore, C.; Armanini, D. Effect of aldosterone and glycyrrhetinic acid on the protein expression of pai-1 and p22(phox) in human mononuclear leukocytes. J. Clin. Endocrinol. Metab. 2004, 89, 1262–1270. [CrossRef]

51. Stürmer, F.C.; Reistad, R.; Alexander, J. Glycyrhizic acid in liquorice—Evaluation of health hazard. Food Chem. Toxicol. 1993, 31, 303–312. [CrossRef]

52. Stewart, P.M.; Wallace, A.M.; Valentino, R.; Burt, D.; Shackleton, C.H.; Edwards, C.R. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987, 2, 821–824. [CrossRef]

53. Ferrari, P. The role of 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. Biochim. Biophys. Acta 2010, 1802, 1178–1187. [CrossRef] [PubMed]

54. Atanasov, A.G.; Ignatova, I.D.; Nashev, L.G.; Dick, B.; Ferrari, P.; Frey, F.J.; Odermatt, A. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: A novel mechanism of apparent mineralocorticoid excess. J. Am. Soc. Nephrol. 2007, 18, 1262–1270. [CrossRef] [PubMed]

55. Christy, C.; Hadoke, P.W.; Paterson, J.M.; Mullins, J.J.; Seckl, J.R.; Walker, B.R. 11beta-hydroxysteroid dehydrogenase type 2 in mouse aorta: Localization and influence on response to glucocorticoids. Hypertension 2003, 42, 580–587. [CrossRef]

56. Lombes, M.; Alfaidy, N.; Eugene, E.; Lessana, A.; Farman, N.; Bonvialt, J.P. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995, 92, 175–182. [CrossRef] [PubMed]

57. Hadoke, P.W.; Christy, C.; Kotelevtsev, Y.V.; Williams, B.C.; Kenyon, C.J.; Seckl, J.R.; Mullins, J.J.; Walker, B.R. Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase. Circulation 2001, 104, 2832–2837. [CrossRef]

58. Van Uum, S.H. Liquorice and hypertension. Neth. J. Med. 2005, 63, 119–120.

59. Monder, C.; Stewart, P.M.; Lakshmi, V.; Valentino, R.; Burt, D.; Edwards, C.R. Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: In vivo and in vitro studies. Endocrinology 1989, 125, 1046–1053. [CrossRef]

60. Tanahashi, T.; Mune, T.; Morita, H.; Tanahashi, H.; Isomura, Y.; Suwa, T.; Daido, H.; Gomez-Sanchez, C.E.; Yasuda, K. Glycyrrhizic acid suppresses type 2 11 beta-hydroxysteroid dehydrogenase expression in vivo. J. Steroid Biochem. Mol. Biol. 2002, 80, 441–447. [CrossRef]

61. Kato, H.; Kanaoka, M.; Yano, S.; Kobayashi, M. 3-monogluconuronyl-glycyrrhetinic acid is a major metabolite that causes licorice-induced pseudoaldosteronism. J. Clin. Endocrinol. Metab. 1995, 80, 1929–1933. [CrossRef]

62. Hammer, F.; Stewart, P.M. Cortisol metabolism in hypertension. Best Pract. Res. Clin. Endocrinol. Metab. 2006, 20, 337–353. [CrossRef] [PubMed]
63. Souness, G.W.; Brem, A.S.; Morris, D.J. 11 beta-hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism. Steroids 2002, 67, 195–201. [CrossRef]

64. Latif, S.A.; Conca, T.J.; Morris, D.J. The effects of the licorice derivative, glycyrrhetinic acid, on hepatic 3α- and 3β-hydroxysteroid dehydrogenases and 5α- and 5β-reductase pathways of metabolism of aldosterone in male rats. Steroids 1990, 55, 52–58. [CrossRef]

65. Chanda, D.; Prieto-Lloret, J.; Singh, A.; Iqbal, H.; Yadav, P.; Snetkov, V.; Aaronson, P.I. Glabridin-induced vasorelaxation: Evidence for a role of bKca channels and cyclic gmp. Life Sci. 2016, 165, 26–34. [CrossRef] [PubMed]

66. Farese, R.V., Jr.; Biglieri, E.G.; Shackleton, C.H.; Irony, I.; Gomez-Fontes, R. Licorice-induced hypokalaemia and water retention in severe human essential hypertension. J. Hypertens. 1997, 15, 57–63. [CrossRef]

67. Ergul, S.; Parish, D.C.; Puett, D.; Ergul, A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 1996, 28, 652–655. [CrossRef]

68. Gomez-Sanchez, E.P.; Gomez-Sanchez, C.E. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. An. J. Physiol. 1992, 263, E1125–E1130. [CrossRef] [PubMed]

69. Hautaniemi, E.J.; Tahvanainen, A.M.; Koskela, J.K.; Tikkakoski, A.J.; Kähönen, M.; Uitto, M.; Sipilä, K.; Ohtake, M.; Hattori, T.; Murase, T.; Takahashi, K.; Takatsu, M.; Ohtake, M.; Miyachi, M.; Watanabe, S.; Cheng, X.W.; Murohara, T.; et al. Glucocorticoids activate cardiac mineralocorticoid receptors in adrenalectomized dahl salt-sensitive rats. Nagoya J. Med. Sci. 2014, 76, 59–72.

70. Ohtake, M.; Hattori, T.; Murase, T.; Takahashi, K.; Takatsu, M.; Ohtake, M.; Miyachi, M.; Watanabe, S.; Schi, ff; et al. Echocardiographic findings of cerebral vascular accident caused by alcohol-free licorice. Presse Med. 1997, 16, 184–185. [CrossRef]

71. Ergul, S.; Parish, D.C.; Puett, D.; Ergul, A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 1996, 28, 652–655. [CrossRef]

72. Hasegawa, J.; Suyama, Y.; Kinugawa, T.; Morisawa, T.; Shimoto, Y. Echocardiographic findings of cerebral vascular accident caused by alcohol-free licorice. Presse Med. 1997, 16, 184–185. [CrossRef]

73. Chamberlain, J.J.; Abolnik, I.Z. Pulmonary edema following a licorice binge. West J. Med. 1997, 167, 184–185. [CrossRef]

74. Chamberlain, T.J. Licorice poisoning, pseudoaldosteronism, and heart failure. JAMA 1970, 213, 1343. [CrossRef]

75. Basso, A.; Dalla Paola, L.; Erle, G.; Boscaro, M.; Armanini, D. Licorice ameliorates postural hypotension in severe human essential hypertension. J. Hypertens. 1997, 15, 57–63. [CrossRef]

76. Van Gelderen, C.E.; Bijlsma, J.A.; van Dokkum, W.; Savelkoul, T.J. Glycyrrhizic acid: The assessment of a no effect level. Hum. Exp. Toxicol. 2000, 19, 434–439. [CrossRef]

77. Basso, A.; Dalla Paola, L.; Erle, G.; Boscaro, M.; Armanini, D. Licorice ameliorates postural hypotension caused by diabetic autonomic neuropathy. Diabetes Care 1994, 17, 1356. [CrossRef]

78. Van der Zwan, A. Hypertension encephalopathy after liquorice ingestion. Clin. Neurol. Neurosurg. 1993, 95, 35–37. [CrossRef]

79. Basso, A.; Dalla Paola, L.; Erle, G.; Boscaro, M.; Armanini, D. Licorice ameliorates postural hypotension caused by diabetic autonomic neuropathy. Diabetes Care 1994, 17, 1356. [CrossRef]

80. Chamberlain, J.J.; Abolnik, I.Z. Pulmonary edema following a licorice binge. West J. Med. 1997, 167, 184–185. [CrossRef]

81. Chamberlain, T.J. Licorice poisoning, pseudoaldosteronism, and heart failure. JAMA 1970, 213, 1343. [CrossRef]

82. Rev. Med. Interne 1993, 52–58. [CrossRef] [PubMed]

83. Tarjus, A.; Amador, C.; Michea, L.; Jaisser, F. Vascular mineralocorticoid receptor and blood pressure regulation. Curr. Opin. Pharmacol. 2015, 21, 138–144. [CrossRef]

84. Johns, C. Glycyrrhizic acid toxicity caused by consumption of licorice candy cigars. CJEM 2009, 11, 94–96. [CrossRef] [PubMed]

85. Francini-Pesenti, F.; Puato, M.; Piccoli, A.; Brocadello, F. Liquorice-induced hypokalaemia and water retention in the absence of hypertension. Phytother. Res. 2008, 22, 563–565. [CrossRef] [PubMed]
86. Negro, A.; Rossi, E.; Regolisti, G.; Perazzoli, F. Liquorice-induced sodium retention. Merely an acquired condition of apparent mineralocorticoid excess? A case report. Ann. Ital. Med. Int. 2000, 15, 296–300.

87. Luis, A.; Domingues, F.; Pereira, L. Metabolic changes after licorice consumption: A systematic review with meta-analysis and trial sequential analysis of clinical trials. Phytomedicine 2018, 39, 17–24. [CrossRef]

88. Forslund, T.; Fyhrquist, F.; Froseth, B.; Tikkanen, I. Effects of licorice on plasma atrial natriuretic peptide in healthy volunteers. J. Intern. Med. 1989, 225, 95–99. [CrossRef]

89. Mattarello, M.J.; Benedini, S.; Fiore, C.; Camozzi, V.; Sartorato, P.; Luissetto, G.; Armanini, D. Effect of licorice on PTH levels in healthy women. Steroids 2006, 71, 403–408. [CrossRef]

90. Sigurjonsdottir, H.A.; Axelson, M.; Johannsson, G.; Manhem, K.; Nystöm, E.; Wallerstedt, S. The liqueuric effect on the RAAS differs between the genders. Blood Press 2006, 15, 169–172. [CrossRef]

91. Ruszymah, B.H.; Nabishah, B.M.; Aminuddin, S.; Khalid, B.A. Effects of glycyrrhizic acid on right atrial pressure and pulmonary vasculature in rats. Clin. Exp. Hypertens. 1995, 17, 575–591. [CrossRef]

92. Yang, P.-S.; Kim, D.-H.; Lee, Y.J.; Lee, S.-E.; Kang, W.J.; Chang, H.-J.; Shin, J.-S. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates macroglossia-induced pulmonary hypertension and vascular remodeling in rats. Respir. Res. 2014, 15, 148. [CrossRef] [PubMed]

93. Ottenbacher, R.; Blehm, J. An unusual case of licorice-induced hypertensive crisis. S. D. Med. 2015, 68, 346–347. [PubMed]

94. Schulze zur Wiesch, C.; Sauer, N.; Aberle, J. Hypertension and hypokalemia—A reninoma as the cause of suspected liquorice-induced arterial hypertension. Dtsch. Med. Wochenschr. 2011, 136, 882–884. [CrossRef] [PubMed]

95. Epstein, M.T.; Espiner, E.A.; Donald, R.A.; Hughes, H. Liquorice toxicity and the renin-angiotensin-aldosterone axis in man. BMJ 1977, 1, 209–210. [CrossRef] [PubMed]

96. Sigurjonsdottir, H.A.; Manhem, K.; Axelson, M.; Wallerstedt, S. Subjects with essential hypertension are more sensitive to the inhibition of 11 beta-hsd by liquorice. J. Hum. Hypertens. 2003, 17, 125–131. [CrossRef] [PubMed]

97. Epstein, M.T.; Espiner, E.A.; Donald, R.A.; Hughes, H. Effect of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects. Br. Med. J. 1977, 1, 488–490. [CrossRef]

98. MacKenzie, M.A.; Hoefnagels, W.H.; Jansen, R.W.; Benraad, T.J.; Kloppenborg, P.W. The influence of glycyrrhetic acid on plasma cortisol and cortisone in healthy young volunteers. J. Clin. Endocrinol. Metab. 1990, 70, 1637–1643. [CrossRef]

99. Kageyama, Y.; Suzuki, H.; Saruta, T. Glycyrrhizin induces mineralocorticoid activity through alterations in cortisol metabolism in the human kidney. J. Endocrinol. 1992, 135, 147–152. [CrossRef]

100. Bernardi, M.; D’Intino, P.E.; Trevisani, F.; Cantelli-Forti, G.; Raggi, M.A.; Turchetto, E.; Gasbarrini, G. Effects of prolonged ingestion of graded doses of licorice by healthy volunteers. Life Sci. 1994, 55, 863–872. [CrossRef]

101. Armanini, D.; Lewicka, S.; Pratesi, C.; Scali, M.; Zennaro, M.C.; Zovato, S.; Gottardo, C.; Simoncini, M.; Spigariol, A.; Zampollo, V. Further studies on the mechanism of the mineralocorticoid action of licorice in humans. J. Endocrinol. Invest. 1996, 19, 624–629. [CrossRef]

102. Sobieszczzyk, P.; Borlaug, B.A.; Gornik, H.L.; Knauf, W.D.; Beckman, J.A. Glycyrrhetinic acid attenuates vascular smooth muscle vasodilatory function in healthy humans. Clin. Sci. 2010, 119, 437–442. [CrossRef] [PubMed]

103. Tu, J.H.; He, Y.J.; Chen, Y.; Fan, L.; Zhang, W.; Tan, Z.R.; Huang, Y.F.; Guo, D.; Hu, D.L.; Wang, D.; et al. Effect of glycyrrhizin on the activity of cyp3a enzyme in humans. Eur. J. Clin. Pharmacol. 2010, 66, 805–810. [CrossRef] [PubMed]

104. Yan, M.; Fang, P.-F.; Li, H.-D.; Xu, P.; Liu, Y.-P.; Wang, F.; Cai, H.-L.; Tan, Q.-Y. Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the p-glycoprotein substrate talinolol in healthy volunteers. Eur. J. Clin. Pharmacol. 2013, 69, 515–521. [CrossRef] [PubMed]

105. Bocker, D.; Breithardt, G. Induction of arrhythmia by licorice abuse. Z. Kardiol. 1991, 80, 389–391. [PubMed]

106. Eriksson, J.W.; Carlberg, B.; Hillorn, V. Life-threatening ventricular tachycardia due to liquorice-induced hypokalaemia. J. Intern. Med. 1999, 245, 307–310. [CrossRef] [PubMed]

107. Bannister, B.; Ginsburg, R.; Shneerson, J. Cardiac arrest due to liquorice induced hypokalaemia. BMJ 1977, 2, 738–739. [CrossRef]

108. Crean, A.M.; Abdel-Rahman, S.E.; Greenwood, J.P. A sweet tooth as the root cause of cardiac arrest. Can. J. Cardiol. 2009, 25, e357–e358. [CrossRef]
109. Campana, A.; Manzo, M.; Brigante, M.; Marrazzo, N.; Melchiorre, G. An unusual cause of cardiac arrest. *Ital. Heart J. Suppl.* 2003, 4, 510–513.

110. Konik, E.; Kurtz, E.G.; Sam, F.; Sawyer, D. Coronary artery spasm, hypertension, hypokalemia and licorice. *J. Clin. Case Rep.* 2012, 2, 143. [CrossRef]

111. Tapolska, M.; Spalek, M.; Szymbowicz, U.; Domin, R.; Owsik, K.; Sochacka, K.; Skrypnik, D.; Bogdański, P.; Owecki, M. Arterial Stiffness Parameters Correlate with Estimated Cardiovascular Risk in Humans: A Clinical Study. *Int. J. Environ. Res. Public Health* 2019, 16, 2547. [CrossRef]

112. Banerjee, A.; Giri, R. Chapter 9—Nutraceuticals in gastrointestinal disorders. In *Nutraceuticals*; Gupta, R.C., Ed.; Academic Press: Boston, MA, USA, 2016; pp. 109–122.

113. Ojha, S.K.; Sharma, C.; Golechha, M.J.; Bhatia, J.; Kumari, S.; Arya, D.S. Licorice treatment prevents oxidative stress, restores cardiac function, and salvages myocardium in rat model of myocardial injury. *Toxicol. Ind. Health* 2015, 31, 140–152. [CrossRef] [PubMed]

114. Ojha, S.; Golechha, M.; Kumari, S.; Bhatia, J.; Arya, D.S. Glycyrrhiza glabra protects from myocardial ischemia–reperfusion injury by improving hemodynamic, biochemical, histopathological and ventricular function. *Exp. Toxicol. Pathol.* 2013, 65, 219–227. [CrossRef] [PubMed]

115. Haleagrahara, N.; Varkkey, J.; Chakravarthi, S. Cardioprotective effects of glycyrrhizinic acid against isoproterenol-induced myocardial ischemia in rats. *Int. J. Mol. Sci.* 2011, 12, 7100–7113. [CrossRef] [PubMed]

116. Fuhrman, B.; Buch, S.; Vaya, J.; Belinky, P.A.; Coleman, R.; Hayek, T.; Aviram, M. Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: In vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein e-deficient mice. *Am. J. Clin. Nutr.* 1997, 66, 267–275. [CrossRef] [PubMed]

117. Rosenblat, M.; Belinky, P.; Vaya, J.; Levy, R.; Hayek, T.; Coleman, R.; Merchav, S.; Aviram, M. Macrophage enrichment with the isoflavan glabridin inhibits naph oxidase-induced cell-mediated oxidation of low density lipoprotein. A possible role for protein kinase C. *J. Biol. Chem.* 1999, 274, 13790–13799. [CrossRef]

118. Somjen, D.; Knoll, E.; Vaya, J.; Stern, N.; Tamir, S. Estrogen-like activity of licorice root constituents: Glabridin and glabrene, in vascular tissues in vitro and in vivo. *J. Steroid Biochem. Mol. Biol.* 2004, 91, 147–155. [CrossRef]

119. Somjen, D.; Kohen, F.; Jaffe, A.; Amir-Zaltsman, Y.; Knoll, E.; Stern, N. Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells. *Hypertension* 1998, 32, 39–45. [CrossRef]

120. Huang, K.; Liu, Y.; Tang, H.; Qiu, M.; Li, C.; Duan, C.; Wang, C.; Yang, J.; Zhou, X. Glabridin prevents doxorubicin-induced cardiotoxicity through gut microbiota modulation and colonic macrophage polarization in mice. *Front. Pharmacol.* 2019. [CrossRef]

121. Meyer, R. Pseudohyperaldosteronismus: Lakritzverzehr mit Folgen. *Dtsch. Arztebl. Int.* 2000, 97, A-596.

122. Wang, X.; Zhang, H.; Chen, L.; Shan, L.; Fan, G.; Gao, X. Liquorice, a unique “guide drug” of traditional Chinese medicine: A review of its role in drug interactions. *J. Ethnopharmacol.* 2013, 150, 781–790. [CrossRef]

123. Tsukamoto, S.; Aburatani, M.; Yoshida, T.; Yamashita, Y.; El-Beih, A.A.; Ohta, T. Cyp3a4 inhibitors isolated from licorice. *Biol. Pharm. Bull.* 2005, 28, 2000–2002. [CrossRef] [PubMed]

124. Kent, U.M.; Aviram, M.; Rosenblat, M.; Aviram, M. Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: In vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein e-deficient mice. *Am. J. Clin. Nutr.* 1997, 66, 267–275. [CrossRef] [PubMed]

125. Ly, Q.L.; Wang, G.H.; Chen, S.H.; Hu, L.; Zhang, X.; Ying, G.; Qin, C.Z.; Zhou, H.H. In vitro and in vivo inhibitory effects of glycyrrhetinic acid in mice and human cytochrome p450 3a4. *Drug Metab. Dispos.* 2002, 30, 709–715. [CrossRef] [PubMed]

126. Paolini, M.; Barillari, J.; Broccoli, M.; Pozzetti, L.; Perocco, P.; Cantelli-Forti, G. Effect of liquorice and glycyrrhizin on rat liver carcinogen metabolizing enzymes. *Cancer Lett.* 1999, 145, 35–42. [CrossRef]

127. Paolini, M.; Pozzetti, L.; Sapone, A.; Cantelli-Forti, G. Effect of licorice and glycyrrhizin on murine liver cyp-dependent monoxygenases. *Life Sci.* 1998, 62, 571–582. [CrossRef]

128. Hou, Y.C.; Lin, S.P.; Chao, P.D. Liquorice reduced cyclosporine bioavailability by activating p-glycoprotein and cyp 3a. *Food Chem.* 2012, 135, 2307–2312. [CrossRef]

129. Heck, A.M.; DeWitt, B.A.; Lukes, A.L. Potential interactions between alternative therapies and warfarin. *Am. J. Health Syst. Pharm.* 2000, 57, 1221–1227, quiz 1228–1230. [CrossRef]
130. Matsumoto, T.; Kaifuchi, N.; Mizuhara, Y.; Warabi, E.; Watanabe, J. Use of a caco-2 permeability assay to evaluate the effects of several kampo medicines on the drug transporter p-glycoprotein. J. Nat. Med. 2018, 72, 897–904. [CrossRef]

131. Kerstens, M.N.; Dullaart, R.P. 11 beta-hydroxysteroid-dehydrogenase: Characteristics and the clinical significance of a key enzyme in cortisol metabolism. Ned. Tijdschr. Geneeskd. 1999, 143, 509–514.

132. Buhl, L.F.; Pedersen, F.N.; Andersen, M.S.; Glintborg, D. Licorice-induced apparent mineralocorticoid excess compounded by excessive use of terbutaline and high water intake. BMJ Case Rep. 2018. [CrossRef]

133. Harada, T.; Ohtaki, E.; Misu, K.; Sumiyoshi, T.; Hosoda, S. Congestive heart failure caused by digitalis toxicity in an elderly man taking a licorice-containing chinese herbal laxative. Cardiology 2002, 98, 218. [CrossRef] [PubMed]

134. Scientific Committee on Food. Opinion of the Scientific Committee on Food on Glycyrrhizinic acid and Its Ammonium Salt; Scientific Committee on Food: Brussels, Belgium, 2003.

135. Shimada, S.; Arai, T.; Tamaoka, A.; Homma, M. Liquorice-induced hypokalaemia in patients treated with yokukansan preparations: Identification of the risk factors in a retrospective cohort study. BMJ Open 2017, 7, e014218. [CrossRef] [PubMed]

136. Segal, R.; Pisanty, S.; Wormser, R.; Azaz, E.; Sela, M.N. Anticariogenic activity of licorice and glycyrrhizine i: Inhibition of in vitro plaque formation by streptococcus mutans. J. Pharm. Sci. 1985, 74, 79–81. [CrossRef] [PubMed]

137. Peskar, B.M. Effect of carbenoxolone on prostaglandin synthesizing and metabolizing enzymes and correlation with gastric mucosal carbenoxolone concentrations. Scand. J. Gastroenterol. Suppl. 1980, 65, 109–114.

138. Asl, M.N.; Hosseinzadeh, H. Review of pharmacological effects of Glycyrrhiza sp. And its bioactive compounds. Phytother. Res. 2008, 22, 709–724. [CrossRef] [PubMed]